Stocklytics Platform
Asset logo for symbol ADMA
ADMA Biologics
ADMA84
$12.78arrow_drop_up3.81%$0.47
High Quality
High Growth
Asset logo for symbol ADMA
ADMA84

$12.78

arrow_drop_up3.81%

Income Statement (ADMA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT$21.82M$14.23M$8.96M-$71.60K-$813.31K
EBITDA$23.93M$16.34M$11.05M$2.02M-$494.49K
gross Profit$38.91M$30.89M$24.65M$16.69M$16.51M
NET Income$17.80M-$17.64M$2.56M-$6.37M-$12.76M
total Revenue$81.87M$73.90M$67.27M$60.12M$56.91M

Balance Sheet (ADMA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt$96.10M$90.06M$78.81M$89.00M$86.52M
stockholders Equity$153.70M$135.20M$151.43M$146.76M$145.65M
total Assets$350.87M$329.18M$348.99M$343.02M$340.78M
total Debt$141.42M$141.41M$152.97M$151.51M$155.72M
total Liabilities$197.16M$193.97M$197.55M$196.26M$195.13M

Cash Flow (ADMA)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow-$1.44M-$38.99M$415.35K$240.11K-$650.50K
free Cash Flow-$4.58M$16.18M$11.22M-$6.93M-$16.66M
investing Cash Flow----$872.63K-$1.94M
operating Cash Flow-$2.21M$17.59M$11.98M-$6.05M-$14.72M

ADMA Biologics (ADMA) Financials

ADMA Biologics Inc (ADMA) is a biopharmaceutical company that specializes in the development and commercialization of plasma-derived biologics for the treatment of infectious diseases. The company's primary focus is on the manufacturing and marketing of specialty plasma-derived immunoglobulin products. ADMA's products are used to treat patients with primary immune deficiency disorders and certain other immune deficiencies. The company's key products include BIVIGAM, ASCENIV, and NABI-HB. BIVIGAM is a intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency (PI). ASCENIV is an intravenous immune globulin indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD). NABI-HB is a hyperimmune globulin indicated for the treatment of hepatitis B infection.

In terms of financials, ADMA Biologics Inc reported total revenue of $64.8 million for the fiscal year ending December 31, 2020. This represents a significant increase from the previous year's revenue of $43.2 million. The company's gross profit for the same period was $38.4 million, with a gross profit margin of 59%. ADMA's net income from stockholders for the year was $10.2 million, compared to a net loss of $18.9 million in the previous year. The company's EBITDA for 2020 was $11.6 million, while EBIT was $4.8 million. ADMA has a strong balance sheet, with total assets of $155.2 million and total liabilities of $118.2 million as of December 31, 2020.

ADMA Biologics Inc has a healthy cash position, with cash equivalents amounting to $62.1 million as of the end of FY2020. The company also has a positive stockholders' equity of $36.3 million. ADMA's total debt stands at $54.6 million, indicating a relatively low level of debt. In terms of cash flow, the company reported operating cash flow of $4.4 million for the fiscal year, reflecting its ability to generate cash from its core operations. ADMA's investing cash flow was negative $1.5 million, primarily due to investments in property and equipment. The company's financing cash flow was positive $30.2 million, primarily driven by proceeds from the issuance of common stock.

In conclusion, ADMA Biologics Inc is a biopharmaceutical company that has achieved significant growth in revenue and profitability. The company's strong financial performance is supported by its portfolio of specialty plasma-derived immunoglobulin products. ADMA's solid balance sheet, healthy cash position, and positive cash flow demonstrate its financial stability and ability to invest in future growth opportunities. With a focus on the treatment of infectious diseases, ADMA is well-positioned to continue expanding its product portfolio and capturing market share.

add ADMA Biologics  to watchlist

Keep an eye on ADMA Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level